Ifp Advisors, Inc Cel Sci Corp Transaction History

Ifp Advisors, Inc

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$1.99 - $3.52 $1,850 - $3,273	-930 Reduced 84.62%	169 $4,000
Q2 2022 Sep 06, 2022	BUY	$2.58 - $4.99 $2,835 - $5,484	1,099 New	1,099 $7,000
Q2 2022 Aug 12, 2022	SELL	$2.58 - $4.99 $2,835 - $5,484	-1,099 Closed	0 $0
Q1 2022 Sep 06, 2022	SELL	$3.93 - $7.7 $3,395 - $6,652	-864 Reduced 44.01%	1,099 $4,000
Q4 2021 Jan 12, 2022	SELL	$7.1 - $12.82 $43,132 - $77,881	-6,075 Reduced 75.58%	1,963 $15,000
Q3 2021 Oct 06, 2021	SELL	$7.64 - $12.49 $12,369 - $20,221	-1,619 Reduced 16.77%	8,038 $89,000
Q2 2021 Jul 13, 2021	BUY	$8.68 - $27.49 $9,600 - $30,403	1,106 Added 12.93%	9,657 $85,000
Q1 2021 Apr 30, 2021	BUY	$12.0 - $27.64 $4,092 - $9,425	341 Added 4.15%	8,551 $129,000
Q4 2020 Jan 25, 2021	BUY	$11.05 - $16.62 $629 - $947	57 Added 0.7%	8,210 $96,000
Q3 2020 Oct 29, 2020	BUY	$11.69 - $14.54 $6,698 - $8,331	573 Added 7.56%	8,153 $103,000
Q2 2020 Aug 05, 2020	SELL	$9.75 - $17.6 $12,138 - $21,912	-1,245 Reduced 14.11%	7,580 $120,000
Q1 2020 May 12, 2020	SELL	$7.54 - $17.05 $37,700 - $85,250	-5,000 Reduced 36.17%	8,825 $107,000
Q4 2019 Jan 17, 2020	BUY	$6.71 - $9.55 $23,485 - $33,425	3,500 Added 33.9%	13,825 $118,000
Q3 2019 Nov 07, 2019	BUY	$6.0 - $9.6 $61,950 - $99,120	10,325 New	10,325 $92,000
Q4 2017 Jan 24, 2018	SELL	$1.63 - $2.0 $13 - $16	-8 Closed	0 $0
Q2 2017 Jun 03, 2019	BUY	N/A	8	8 $0

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $30.4M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.